1. Home
  2. GRND vs AKRO Comparison

GRND vs AKRO Comparison

Compare GRND & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GRND
  • AKRO
  • Stock Information
  • Founded
  • GRND 2009
  • AKRO 2017
  • Country
  • GRND United States
  • AKRO United States
  • Employees
  • GRND N/A
  • AKRO N/A
  • Industry
  • GRND Computer Software: Prepackaged Software
  • AKRO Biotechnology: Pharmaceutical Preparations
  • Sector
  • GRND Technology
  • AKRO Health Care
  • Exchange
  • GRND Nasdaq
  • AKRO Nasdaq
  • Market Cap
  • GRND 2.1B
  • AKRO 2.1B
  • IPO Year
  • GRND N/A
  • AKRO 2019
  • Fundamental
  • Price
  • GRND $13.65
  • AKRO $31.59
  • Analyst Decision
  • GRND Strong Buy
  • AKRO Strong Buy
  • Analyst Count
  • GRND 3
  • AKRO 7
  • Target Price
  • GRND $15.33
  • AKRO $43.20
  • AVG Volume (30 Days)
  • GRND 464.9K
  • AKRO 441.5K
  • Earning Date
  • GRND 11-07-2024
  • AKRO 11-11-2024
  • Dividend Yield
  • GRND N/A
  • AKRO N/A
  • EPS Growth
  • GRND N/A
  • AKRO N/A
  • EPS
  • GRND N/A
  • AKRO N/A
  • Revenue
  • GRND $300,034,000.00
  • AKRO N/A
  • Revenue This Year
  • GRND $30.64
  • AKRO N/A
  • Revenue Next Year
  • GRND $21.70
  • AKRO N/A
  • P/E Ratio
  • GRND N/A
  • AKRO N/A
  • Revenue Growth
  • GRND 34.98
  • AKRO N/A
  • 52 Week Low
  • GRND $5.71
  • AKRO $11.36
  • 52 Week High
  • GRND $13.90
  • AKRO $37.00
  • Technical
  • Relative Strength Index (RSI)
  • GRND 63.17
  • AKRO 66.34
  • Support Level
  • GRND $13.06
  • AKRO $29.34
  • Resistance Level
  • GRND $13.90
  • AKRO $32.15
  • Average True Range (ATR)
  • GRND 0.42
  • AKRO 1.26
  • MACD
  • GRND 0.06
  • AKRO 0.10
  • Stochastic Oscillator
  • GRND 80.54
  • AKRO 99.74

About GRND Grindr Inc.

Grindr Inc is a social networking app for gay, bi, trans, and queer people. It is a social network that brings together gay and bisexual men who want to meet other men close to them in a completely discreet and anonymous way, without having to give any personal information or having to fill out a profile with confidential information in order to register.

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

Share on Social Networks: